Effects of arginine derivatives on soluble guanylate cyclase from neuroblastoma N1E 115 cells. 1990

M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.

The effects of L-arginine (Arg) derivatives on soluble guanylate cyclase from neuroblastoma N1E 115 cells were examined. The Arg derivatives were modified at the -NH2, -COOH, C alpha-proton or guanidino group of Arg. Among the synthesized derivatives, eight compounds, i.e. the 5-(dimethylamino)-1-naphthalenesulfonyl (DNS) ones, especially N-cyclohexyl-2-(N-DNSamino)-5-guanidino-2-methylvaleramide and 1-[2-(N-DNSamino)-2-(2-imino-1,2,3,4,5,6-hexahydropyrimidin- 4-yl)acetyl]- piperidine, were found to inhibit the activity of crude guanylate cyclase in the 105,000 g supernatant fraction of the cell homogenate. The enzyme, partially purified by a column of Chelex 100 Na+, was also inhibited by these eight compounds. The mode of the inhibition was competitive. The Ki values were in the range of 2-8 microM for the enzyme in the 105,000 g supernatant fraction and 3-16 microM for the partially purified enzyme, in the presence of Mg2+ as a metal cofactor. In contrast, a new derivative, methyl 2-amino-5-guanidinovalerate (M Arg ME), as well as the Arg methyl ester (Arg ME) and Arg; were found to enhance the activity of the partially purified guanylate cyclase; KA values of M Arg ME, Arg ME and Arg were approximately 9, 4 and 3 microM respectively. From these results, the free guanidino group including 2-imino-1,2,3,4,5,6-hexahydropyrimidin-4-yl or 2-imino-1,2,3,4,5,6-hexahydropyrimidin-5-yl and modification of the --NH2 residue with a hydrophobic group such as DNS seemed to be essential for inhibition of the guanylate cyclase; however, the guanidino and --NH2 residue of Arg should be free for activation by these Arg derivatives.

UI MeSH Term Description Entries
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D003619 Dansyl Compounds Compounds that contain a 1-dimethylaminonaphthalene-5-sulfonyl group. Dimethylaminonaphthalenesulfonyl Compounds,Compounds, Dansyl,Compounds, Dimethylaminonaphthalenesulfonyl
D006160 Guanosine Triphosphate Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. GTP,Triphosphate, Guanosine
D006162 Guanylate Cyclase An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2. Guanyl Cyclase,Deoxyguanylate Cyclase,Guanylyl Cyclase,Inosinate Cyclase,Cyclase, Deoxyguanylate,Cyclase, Guanyl,Cyclase, Guanylate,Cyclase, Guanylyl,Cyclase, Inosinate
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
January 1979, Journal of cyclic nucleotide research,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
February 1991, The Biochemical journal,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
February 1986, The Journal of pharmacology and experimental therapeutics,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
September 1982, The Journal of biological chemistry,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
May 1986, Acta physiologica Scandinavica,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
January 1990, Journal of pineal research,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
January 1989, Nutrition and cancer,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
January 1990, Experimental gerontology,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
January 1989, Tissue & cell,
M Yoshioka, and H Fujimori, and T Deguchi, and H Masayasu, and K Suzuki, and K Inamura, and A Kosasayama, and F Ishikawa
January 1991, Neurotoxicology,
Copied contents to your clipboard!